Listen Here:
Click or simply search “Sigma Nutrition” on your podcast platform of choice.
Or listen directly on the Sigma website here.
Introduction
It has been clearly demonstrated that elevated LDL-cholesterol (LDL-C), or perhaps more specifically pro-atherogenic lipoproteins, is causal in atherosclerosis development in humans.
One crucial concept within this is that the risk relates not only to the magnitude of elevated LDL-C, but the duration of exposure. Thus, the role of LDL-C in driving atherosclerosis is referred to as a “cumulative, integrated exposure over the lifecourse”.
But, what exactly does this mean?
In this episode, Danny discusses the cumulative exposure model of LDL-C in atherosclerosis, the evidence supporting it, and the implications of this for the “debates” that get raised in relation to LDL-C (or apoB-containing lipoproteins) and heart disease.
Related resources
- Join the Sigma newsletter for free
- Subscribe to Sigma Nutrition Premium
- [01:37]Common claims and narratives
- [03:15]Historical context of dietary guidelines
- [21:57]Sugar industry influence on dietary research
- Glucose Peaks
- Some Pragmatic Considerations
The Hosts
Click through to your app of choice to listen and subscribe:
Dr. Alan Flanagan has a PhD in nutrition from the University of Surrey, where his doctoral research focused on circadian rhythms, feeding, and chrononutrition.
This work was based on human intervention trials. He also has a Masters in Nutritional Medicine from the same institution.
Dr. Flanagan is a regular co-host of Sigma Nutrition Radio. He also produces written content for Sigma Nutrition, as part of his role as Research Communication Officer.
Danny Lennon has a master’s degree (MSc.) in Nutritional Sciences from University College Cork, and he is the founder of Sigma Nutrition.
Danny is currently a member of the Advisory Board of the Sports Nutrition Association, the global regulatory body responsible for the standardisation of best practice in the sports nutrition profession.
Introduction to this Episode
It has been clearly demonstrated that elevated LDL-cholesterol (LDL-C), or perhaps more specifically pro-atherogenic lipoproteins, is causal in atherosclerosis development in humans.
One crucial concept within this is that the risk relates not only to the magnitude of elevated LDL-C, but the duration of exposure.
Thus, the role of LDL-C in driving atherosclerosis is referred to as a “cumulative, integrated exposure over the lifecourse”.
But, what exactly does this mean?
In this episode, Danny discusses the cumulative exposure model of LDL-C in atherosclerosis, the evidence supporting it, and the implications of this for the “debates” that get raised in relation to LDL-C (or apoB-containing lipoproteins) and heart disease.
Connection to Previous Episodes
#381: Prof. Chris Packard – LDL Cholesterol, ApoB & Atherosclerosis
- Chris Packard holds an Honorary Professorship of Vascular Biochemistry at the University of Glasgow.
- Over his career, Professor Packard has focussed on two aspects of atherosclerosis research, lipoprotein metabolism and how it is affected by diets and drugs, and large-scale clinical trials of lipid lowering agents.
- He is acknowledged as one of the leading researchers in the world in this field.
- We cover a lot of ground, including how this cumulative exposure concept is central to the “lower is better” paradigm for LDL-C.
- You can find the episode page here.
